FMOC-3-氨基苯甲酸 | 185116-42-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: FMOC-3-氨基苯甲酸
• 中文别名: N-Fmoc-3-氨基苯甲酸；Fmoc-3-氨基苯甲酸
• 英文名称: 3-(9-fluorenylmethyloxycarbonyl)aminobenzoic acid
• 英文别名: 3-(((9H-fluoren-9-yl)methoxy)carbonylamino)benzoic acid；3-(fmoc-amino)benzoic acid；Fmoc-3-aminobenzoic acid；Fmoc-3-Abz-OH；3-(9H-fluoren-9-ylmethoxycarbonylamino)benzoic acid
• CAS: 185116-42-1
• 化学式: C₂₂H₁₇NO₄
• 分子量: 359.381
• InChiKey: VFXDSSUGFNVDJP-UHFFFAOYSA-N

物化性质

• 沸点：
  548.3±33.0 °C(Predicted)
• 密度：
  1.352±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29242990
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-3-aminobenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-3-aminobenzoic acid
CAS number: 185116-42-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C22H17NO4
Molecular weight: 359.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  FMOC-3-氨基苯甲酸 在 氯化亚砜 作用下， 反应 5.0h， 生成
  参考文献：
  名称：

  Synthesis, Molecular Docking Analysis and Biological Evaluations of Saccharide-Modified Thiadiazole Sulfonamide Derivatives

  摘要：

  一系列糖苷修饰的噻二唑磺胺衍生物已通过“尾部方法”设计和合成，并针对碳酸酐酶II、IX和XII的抑制活性进行评估。大多数化合物显示出较高的拓扑极性表面积（TPSA）值和优秀的酶抑制活性。一些化合物对HT-29、MDA-MB-231和MG-63人类癌细胞系的存活率在常氧和低氧条件下进行了检查，它们显示出一定的细胞存活抑制作用。此外，发现这一系列化合物具有提高肿瘤细胞微环境pH值的能力。所有结果证明，糖苷修饰的噻二唑磺胺具有重要的CA IX抑制剂开发研究前景。

  DOI：

  10.3390/ijms22115482
• 作为产物：
  描述：

  (E)-3-(1-propan-2-ylpiperidin-4-yl)prop-2-enoic acid;hydrochloride 在 三乙基硅烷 、 水 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 FMOC-3-氨基苯甲酸
  参考文献：
  名称：

  Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease

  摘要：

  这项发明涵盖了尿素取代苯甲酸化合物，包括这些化合物的组合物以及通过给予这些化合物或组合物来治疗或预防与mRNA无义突变相关疾病的方法。

  公开号：

  US20060167065A1

文献信息

• [EN] POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO<br/>[FR] POLYCONJUGUÉS POUR L'ADMINISTRATION DE DÉCLENCHEURS D'ARNI À DES CELLULES TUMORALES IN VIVO
  申请人：ARROWHEAD RES CORP

  公开号：WO2015021092A1

  公开（公告）日：2015-02-12

  The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand- targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.

  本发明涉及将RNA干扰（RNAi）触发物传递至体内整合素阳性肿瘤细胞的组合物。这些组合物包括以RGD配体为靶向的两性膜活性多胺，可逆地修饰为酶可切割二肽-酰胺基苄-碳酸酯掩蔽剂。修饰掩盖了聚合物的膜活性，而可逆性提供了生理响应性。这些可逆修饰的多胺（动态多共轭物或共轭物）进一步与RNAi触发物共价连接。
• Diacylhydrazine derivatives
  申请人：Merck Patent GmbH

  公开号：US06649613B1

  公开（公告）日：2003-11-18

  Diacylhydrazine derivatives of general formula (I) wherein X, Y, Z, R1, 2 and R3 are as defined herein, and their physiologically acceptable salts or solvates thereof, are integrin inhibitors and can be used to combat thromboses, myocardial infarcts, coronary cardiac diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections, and restenosis following angioplasty or during pathological processes that are maintained or propagated by angiogenesis.

  通用式（I）的二酰基肼衍生物 其中X、Y、Z、R1、2和R3如本文所定义，并且它们的生理上可接受的盐或溶剂化合物，是整合素抑制剂，可用于对抗血栓形成、心肌梗死、冠心病、动脉粥样硬化、炎症、肿瘤、骨质疏松症、感染，以及在血管成形术后或由血管生成维持或传播的病理过程中的再狭窄。
• Antibacterial evaluation of structurally amphipathic, membrane active small cationic peptidomimetics: Synthesized by incorporating 3-amino benzoic acid as peptidomimetic element
  作者：Sandeep Lohan、Swaranjit Singh Cameotra、Gopal Singh Bisht

  DOI：10.1016/j.ejmech.2014.06.023

  日期：2014.8

  A new series of small cationic peptidomimetics were synthesized by incorporating 3-amino benzoic acid (3-ABA) in a small structural framework with the objective to mimic essential properties of natural antimicrobial peptides (AMPs). The new design approach resulted into improvement of activity and selectivity in comparison to linear peptides and allowed us to better understand the influence of structural

  通过将3-氨基苯甲酸（3-ABA）掺入一个小的结构框架中，以模拟天然抗菌肽（AMPs）的基本特性，合成了一系列新的小型阳离子拟肽。与线性肽相比，新的设计方法提高了活性和选择性，使我们能够更好地了解结构两亲性对生物活性的影响。铅拟肽对耐药性病原体（MRSA和MRSE）显示出抗菌活性。钙黄绿素染料泄漏实验显示出4g和4l的膜溶解作用，这通过荧光显微镜进一步证实。此外，蛋白水解稳定性和对金黄色葡萄球菌无耐药性的迹象 MRSA和MRSA证明了它们作为新型抗菌治疗剂的进一步开发潜力。
• Solid-Phase Synthesis of a Nonpeptide RGD Mimetic Library:  New Selective αvβ3 Integrin Antagonists
  作者：Gábor A. G. Sulyok、Christoph Gibson、Simon L. Goodman、Günter Hölzemann、Matthias Wiesner、Horst Kessler

  DOI：10.1021/jm0004953

  日期：2001.6.1

  solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins alphavbeta3 and alphaIIbbeta3 were determined in a screening assay. Highly active and selective nonpeptide alphavbeta3 integrin antagonists with regard to orally bioavailability were developed

  描述了低分子量RGD模拟物库的固相合成。在筛选分析中确定了化合物在抑制配体，玻连蛋白和纤维蛋白原与分离的固定化整合素αvbeta3和αIIbbeta3相互作用中的活性。基于含氮杂甘氨酸的先导化合物1，开发了具有高活性和选择性的非肽αvbeta3整联蛋白拮抗剂，具有口服生物利用度。一个重要的变化是芳香残基取代了天冬酰胺1。此外，已经引入了不同的胍模拟物以改善药代动力学特征。一组RGD模拟物中的亚甲基部分与β-氨基酸NH的交换产生了代表一种新型拟肽方法的杜鹃花类似物化合物，
• Design and synthesis of potent β-secretase (BACE1) inhibitors with <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si2.gif" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math> carboxylic acid bioisosteres
  作者：Tooru Kimura、Yoshio Hamada、Monika Stochaj、Hayato Ikari、Ayaka Nagamine、Hamdy Abdel-Rahman、Naoto Igawa、Koushi Hidaka、Jeffrey-Tri Nguyen、Kazuki Saito、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2006.01.108

  日期：2006.5

  Recently, we reported potent and small-sized beta-secretase (BACE1) inhibitors KMI-420 and KMI-429 in which we replaced the Glu residue at the P4 position of KMI-260 and KMI-360, respectively, with a 1H-tetrazole-5-carbonyl DAP (L-alpha,beta-diaminopropionic acid) residue. At the P1' position, these compounds contain one or two carboxylic acid groups, which are unfavorable for crossing the blood-brain

  最近，我们报道了强效和小型β-分泌酶（BACE1）抑制剂KMI-420和KMI-429，其中我们分别用1H-四唑取代了KMI-260和KMI-360的P4位置的Glu残基-5-羰基DAP（L-α，β-二氨基丙酸）残基。这些化合物在P1'位置含有一个或两个羧酸基团，不利于穿越血脑屏障。在本文中，我们报道了具有P1'羧酸生物异构体的BACE1抑制剂，以开发实用的抗阿尔茨海默氏病药物。其中，含四唑环的化合物KMI-570（IC50 = 4.8 nM）和KMI-684（IC50 = 1.2 nM）表现出显着的BACE1抑制活性。